Tarsus Q2 Smashes Estimates, Raises Guidance, and Announces Alkeus Acquisition and $125M Placement

summarizeSummary

Tarsus reported Q2 2026 XDEMVY sales of $173.9M (+69% YoY), raised full-year guidance to $685-705M, announced the acquisition of Alkeus Pharmaceuticals for its Phase 3 Stargardt disease program, and priced a $125M private placement.

check_boxKey Events · Earnings and Guidance · TARS

• Q2 XDEMVY Sales Surge 69%

  Net product sales reached $173.9M in Q2 2026, up from $102.7M a year ago, driven by higher volume and improved gross-to-net discounts.

• Full-Year Guidance Raised to $685-705M

  Management lifted 2026 XDEMVY net sales guidance from prior levels, reflecting strong demand and commercial execution.

• Alkeus Acquisition Adds Phase 3 Retina Asset

  Tarsus agreed to acquire Alkeus Pharmaceuticals, gaining ALK-001, a once-daily oral therapy for Stargardt disease affecting over 36,000 U.S. patients, with a Phase 3 program underway.

• $125M Private Placement Priced

  The company priced a $125 million private placement with top-tier funds and existing Alkeus investors, strengthening the balance sheet to fund the acquisition and pipeline.

auto_awesomeAnalysis · TARS · Life Sciences

Tarsus delivered a standout quarter with XDEMVY net sales of $173.9M, up 69% year-over-year, and raised full-year guidance to $685-705M — well above consensus. The company also announced the acquisition of Alkeus Pharmaceuticals, adding a Phase 3 Stargardt disease asset, and priced a $125M private placement. These moves transform the growth narrative: strong commercial execution funds pipeline expansion without balance sheet strain, and the Alkeus deal deepens the retina franchise. The combination of beat-and-raise, strategic M&A, and a well-supported financing makes this a thesis-altering update.